NCT06505967招募中不适用
Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels: A Randomized Double-Blind Parallel Trial
Qualia Life Sciences2 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2024年6月10日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 200
- 试验地点
- 2
- 主要终点
- NAD+ Levels in the Blood
研究概览
简要总结
The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety.
Researchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood.
Participants will:
Take Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text.
- •Healthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study.
- •Willing to not consume any supplements, energy drinks/shots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period.
- •Willing to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements).
- •Willingness to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives researchers access to the results of these tests.
排除标准
- •Women who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances/allergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent
结局指标
主要结局
NAD+ Levels in the Blood
时间窗: 4 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
NAD+ Oral Supplement Pilot Intervention in Adult FemalesNCT06579209University of Rhode Island53
已完成
1 期
NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive ImpairmentMild Cognitive ImpairmentNCT03482167University of Delaware64
已完成
2 期
NAD+ Precursor Supplementation in Friedreich's AtaxiaFriedreich AtaxiaNCT04817111Metro International Biotech, LLC7
已完成
1 期
NAD Supplementation and Vascular Health in PADPeripheral Artery DiseaseNCT06534944University of Oklahoma8
进行中（未招募）
2 期
NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia TelangiectasiaAtaxia TelangiectasiaNCT04870866University Hospital, Akershus13